|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| License revenue | |||||
| License Revenue | |||||
| Total license revenue | |||||
| Collaborative arrangement revenue | |||||
| Total revenue | |||||
| Operating expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| Restructuring costs | |||||
| Goodwill impairment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (loss) | |||||
| Interest income, net | |||||
| Loss on foreign currency transactions | |||||
| Research and development incentive award | |||||
| Gain on fair value adjustments | |||||
| Total other income | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Other comprehensive income | |||||
| Unrealized gain on foreign currency translation | |||||
| Total other comprehensive income | |||||
| Comprehensive loss | |||||
| Net loss per share - basic | |||||
| Net loss per share - diluted | |||||
| Weighted-average common shares outstanding - basic | |||||
| Weighted-average common shares outstanding - diluted | |||||
Loading...